Medical - Healthcare Information Services
Compare Stocks
2 / 10Stock Comparison
SY vs DOCS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
SY vs DOCS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Information Services |
| Market Cap | $198M | $5.24B |
| Revenue (TTM) | $1.43B | $638M |
| Net Income (TTM) | $-741M | $239M |
| Gross Margin | 51.6% | 89.7% |
| Operating Margin | -53.2% | 37.4% |
| Forward P/E | — | 16.8x |
| Total Debt | $240M | $12M |
| Cash & Equiv. | $588M | $210M |
SY vs DOCS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| So-Young Internatio… (SY) | 100 | 31.4 | -68.6% |
| Doximity, Inc. (DOCS) | 100 | 44.7 | -55.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SY vs DOCS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SY is the clearest fit if your priority is dividends and momentum.
- 1.6% yield; 1-year raise streak; the other pay no meaningful dividend
- +266.1% vs DOCS's -55.4%
DOCS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.03
- Rev growth 20.0%, EPS growth 54.2%, 3Y rev CAGR 18.4%
- -50.9% 10Y total return vs SY's -82.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs SY's -2.1% | |
| Quality / Margins | 37.5% margin vs SY's -51.8% | |
| Stability / Safety | Beta 1.03 vs SY's 2.05, lower leverage | |
| Dividends | 1.6% yield; 1-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +266.1% vs DOCS's -55.4% | |
| Efficiency (ROA) | 20.7% ROA vs SY's -28.0%, ROIC 20.0% vs -24.1% |
SY vs DOCS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SY vs DOCS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SY is the larger business by revenue, generating $1.4B annually — 2.2x DOCS's $638M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to SY's -51.8%. On growth, DOCS holds the edge at +9.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.4B | $638M |
| EBITDAEarnings before interest/tax | -$751M | $250M |
| Net IncomeAfter-tax profit | -$741M | $239M |
| Free Cash FlowCash after capex | $0 | $314M |
| Gross MarginGross profit ÷ Revenue | +51.6% | +89.7% |
| Operating MarginEBIT ÷ Revenue | -53.2% | +37.4% |
| Net MarginNet income ÷ Revenue | -51.8% | +37.5% |
| FCF MarginFCF ÷ Revenue | -6.0% | +49.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.0% | +9.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -4.3% | -16.2% |
Valuation Metrics
SY leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $198M | $5.2B |
| Enterprise ValueMkt cap + debt − cash | $147M | $5.0B |
| Trailing P/EPrice ÷ TTM EPS | -4.68x | 23.45x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 16.83x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.30x |
| EV / EBITDAEnterprise value multiple | — | 21.14x |
| Price / SalesMarket cap ÷ Revenue | 0.92x | 9.18x |
| Price / BookPrice ÷ Book value/share | 1.41x | 4.84x |
| Price / FCFMarket cap ÷ FCF | — | 19.64x |
Profitability & Efficiency
DOCS leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
DOCS delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-41 for SY. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to SY's 0.12x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs SY's 2/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -41.4% | +24.4% |
| ROA (TTM)Return on assets | -28.0% | +20.7% |
| ROICReturn on invested capital | -24.1% | +20.0% |
| ROCEReturn on capital employed | -26.1% | +22.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 9 |
| Debt / EquityFinancial leverage | 0.12x | 0.01x |
| Net DebtTotal debt minus cash | -$348M | -$197M |
| Cash & Equiv.Liquid assets | $588M | $210M |
| Total DebtShort + long-term debt | $240M | $12M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
SY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DOCS five years ago would be worth $4,911 today (with dividends reinvested), compared to $3,530 for SY. Over the past 12 months, SY leads with a +266.1% total return vs DOCS's -55.4%. The 3-year compound annual growth rate (CAGR) favors SY at 3.6% vs DOCS's -8.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +13.1% | -39.9% |
| 1-Year ReturnPast 12 months | +266.1% | -55.4% |
| 3-Year ReturnCumulative with dividends | +11.3% | -24.2% |
| 5-Year ReturnCumulative with dividends | -64.7% | -50.9% |
| 10-Year ReturnCumulative with dividends | -82.9% | -50.9% |
| CAGR (3Y)Annualised 3-year return | +3.6% | -8.8% |
Risk & Volatility
Evenly matched — SY and DOCS each lead in 1 of 2 comparable metrics.
Risk & Volatility
DOCS is the less volatile stock with a 1.03 beta — it tends to amplify market swings less than SY's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SY currently trades 48.1% from its 52-week high vs DOCS's 34.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.05x | 1.03x |
| 52-Week HighHighest price in past year | $6.28 | $76.51 |
| 52-Week LowLowest price in past year | $0.80 | $20.55 |
| % of 52W HighCurrent price vs 52-week peak | +48.1% | +34.0% |
| RSI (14)Momentum oscillator 0–100 | 65.7 | 60.1 |
| Avg Volume (50D)Average daily shares traded | 457K | 2.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SY as "Buy" and DOCS as "Buy". Consensus price targets imply 64.4% upside for DOCS (target: $43) vs -73.5% for SY (target: $1). SY is the only dividend payer here at 1.58% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $0.80 | $42.79 |
| # AnalystsCovering analysts | 5 | 22 |
| Dividend YieldAnnual dividend ÷ price | +1.6% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $0.32 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.4% | +2.3% |
DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SY leads in 2 (Valuation Metrics, Total Returns). 1 tied.
SY vs DOCS: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is SY or DOCS a better buy right now?
For growth investors, Doximity, Inc.
(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus -2. 1% for So-Young International Inc. (SY). Doximity, Inc. (DOCS) offers the better valuation at 23. 5x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate So-Young International Inc. (SY) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SY or DOCS?
Over the past 5 years, Doximity, Inc.
(DOCS) delivered a total return of -50. 9%, compared to -64. 7% for So-Young International Inc. (SY). Over 10 years, the gap is even starker: DOCS returned -50. 9% versus SY's -82. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SY or DOCS?
By beta (market sensitivity over 5 years), Doximity, Inc.
(DOCS) is the lower-risk stock at 1. 03β versus So-Young International Inc. 's 2. 05β — meaning SY is approximately 100% more volatile than DOCS relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 12% for So-Young International Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SY or DOCS?
By revenue growth (latest reported year), Doximity, Inc.
(DOCS) is pulling ahead at 20. 0% versus -2. 1% for So-Young International Inc. (SY). On earnings-per-share growth, the picture is similar: Doximity, Inc. grew EPS 54. 2% year-over-year, compared to -28. 4% for So-Young International Inc.. Over a 3-year CAGR, DOCS leads at 18. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SY or DOCS?
Doximity, Inc.
(DOCS) is the more profitable company, earning 39. 1% net margin versus -40. 2% for So-Young International Inc. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -42. 6% for SY. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SY or DOCS more undervalued right now?
Analyst consensus price targets imply the most upside for DOCS: 64.
4% to $42. 79.
07Which pays a better dividend — SY or DOCS?
In this comparison, SY (1.
6% yield) pays a dividend. DOCS does not pay a meaningful dividend and should not be held primarily for income.
08Is SY or DOCS better for a retirement portfolio?
For long-horizon retirement investors, Doximity, Inc.
(DOCS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03)). So-Young International Inc. (SY) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DOCS: -50. 9%, SY: -82. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SY and DOCS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SY is a small-cap quality compounder stock; DOCS is a small-cap high-growth stock. SY pays a dividend while DOCS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.